Berkowitz G S, Kelsey J L, LiVolsi V A, Merino M J, Holford T R, Hildreth N G, Ort S, O'Connor T Z, White C
Int J Cancer. 1984 Oct 15;34(4):443-9. doi: 10.1002/ijc.2910340403.
In a hospital-based case-control study of 590 women with biopsy-proven fibrocystic breast disease and 1,018 control women with other surgical conditions, no linear relationship was evident between the use of oral contraceptives or of estrogen replacement therapy and the degree of epithelial atypia of the fibrocystic lesions. Case-control and intracase comparisons suggested that oral contraceptive use might be associated with an increased occurrence of sclerosing adenosis among the premenopausal women and of gross cysts among the postmenopausal women. Estrogen replacement therapy, which was positively associated with fibrocystic breast disease as a whole among the post-menopausal women, was most frequently used among the cases whose biopsy specimens exhibited gross cysts, papillomatosis or papillary hyperplasia.
在一项基于医院的病例对照研究中，研究对象为590名经活检证实患有纤维囊性乳腺病的女性以及1018名患有其他外科疾病的对照女性。口服避孕药或雌激素替代疗法的使用与纤维囊性病变的上皮异型程度之间未发现明显的线性关系。病例对照和病例内比较表明，使用口服避孕药可能与绝经前女性硬化性腺病的发生率增加以及绝经后女性巨大囊肿的发生率增加有关。雌激素替代疗法在绝经后女性中总体上与纤维囊性乳腺病呈正相关，在活检标本显示有巨大囊肿、乳头状瘤病或乳头状增生的病例中使用最为频繁。
